The chemistry and biological profile of trovafloxacin

Journal of Antimicrobial Chemotherapy

Volumn 39, Issue SUPPL. B, 1997, Pages 1-14

  Brighty, K E ^a   Gootz, T D ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TROVAFLOXACIN;

ANAEROBIC BACTERIUM; ANTIBACTERIAL ACTIVITY; CHEMICAL STRUCTURE; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG POTENCY; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; REVIEW;

EID: 0030757351     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/39.suppl_2.1     Document Type: Review

References (67)

1. Hooper, D. C. & Wolfson, J. S. Eds (1993). Quinolone Antimicrobial Agents, 2nd edn. American Society for Microbiology, Washington, DC.
2. Gootz, T. D. & Brighty, K. E. (1996). Fluoroquinolone antibacterials: SAR, mechanism of action, resistance and clinical aspects. Medicinal Research Reviews 16, 433-86.
3. Menzel, R. & Gellert, M. (1994). The biochemistry and biology of DNA gyrase. Advances in Pharmacology 29A, 39-69.
4. Willmott, C. J. R., Critchlow, S. E., Eperon, I. C. & Maxwell, A, (1994). The complex of DNA gyrase and quinolone drugs with DNA forms a barrier to transcription by RNA polymerase. Journal of Molecular Biology 242, 351-63.
5. Lewin, C. S., Morrissey, I. & Smith, J. T. (1991). The mode of action of quinolones: the paradox in activity of low and high concentrations and activity in the anaerobic environment. European Journal of Clinical Microbiology and Infectious Diseases 10, 240-8.
6. Lewin, C. S. & Smith, J. T. (1988). Bactericidal mechanisms of ofloxacin. Journal of Antimicrobial Chemotherapy 22, Suppl. C, 1-8.
7. Wiedemann, B. & Heisig, P. (1994). Mechanisms of quinolone resistance. Infection 22, Suppl. 2, S73-S79.
8. Kato, J.-I., Nishimura, Y., Imamura, R., Niki, H., Hiraga, S. & Suzuki, H. (1990). New topoisomerase essential for chromosome segregation in E. coli. Cell 63, 393-404.
9. Peng, H. & Marians, K. J. (1993). Escherichia coli topoisomerase IV. Journal of Biological Chemistry 268, 24481-90.
10. Hoshino, K., Kitamura, A., Morrissey, I., Sato, K., Kato, J.-I. & Ikeda, H. (1994). Comparison of inhibition of Escherichia coli topoisomerase IV by quinolones with DNA gyrase inhibition. Antimicrobial Agents and Chemotherapy 38, 2623-7.
11. Khodursky, A. B., Zechiedrich, E. L. & Cozzarelli, N. R. (1995). Topoisomerase IV is a target of quinolones in Escherichia coli. Proceedings of the National Academy of Sciences of the USA 92, 11801-5.
12. Vila, J., Ruiz, J., Goñi, P. & Jimenez de Anta, M. T. (1996). Detection of mutations in parC in quinolone-resistant clinical isolates of Escherichia coli. Antimicrobial Agents and Chemotherapy 40, 491-3.
13. Ferrero, L., Cameron, B. & Crouzet, J. (1995). Analysis of gyrA and grlA mutations in stepwise-selected ciprofloxacin-resistant mutants of Staphylococcus aureus. Antimicrobial Agents and Chemotherapy 39, 1554-8.
14. Rádl, S. & Dax, S. (1994). Quinolone congeners as mammalian topoisomerase II inhibitors. Current Medicinal Chemistry 1, 262-70.
15. Yamashita, Y., Ashizawa, T., Morimoto, M., Hosomi, J. & Nakano, H. (1992). Antitumor quinolones with mammalian topoisomerase II-mediated DNA cleavage activity. Cancer Research 52, 2818-22.
16. Lesher, G. Y., Froelich, E. J., Gruett, M. D., Bailey, J. H. & Brundage, R. P. (1962). 1,8-Naphthyridine derivatives: a new class : of chemotherapeutic agents. Journal of Medicinal Chemistry 5, 1063-5.
17. Koga, H., Itoh, A., Murayama, S., Suzue, S. & Irikura, T. (1980). Structure-activity relationships of antibacterial 6,7- and 7,8-disubstituted 1 -alkyl-1,4-dihydro-4-oxoquinoline-3-carboxylic ; acids. Journal of Medicinal Chemistry 23, 1358-63.
18. Kojima, T., Inoue, M. & Mitsuhashi, S. (1989). In vitro activity of AT-4140 against clinical bacterial isolates. Antimicrobial Agents and Chemotherapy 33, 1980-8.
19. Stahlmann, R. (1990). Safety profile of the quinolones. Journal of Antimicrobial Chemotherapy 26, Suppl. D, 31-44.
20. Domagala, J. M. (1994). Structure-activity and structureside-effect relationships for the quinolone antibacterials. Journal of Antimicrobial Chemotherapy 33, 685-706.
21. Dagan, R. (1995). Fluoroquinolones in paediatrics-1995. Drugs 49, Suppl. 2, 92-9.
22. Asahina, Y., Ishizaki, T. & Suzue, S. (1992). Recent advances in structure-activity relationships in new quinolones. Progress in Drug Research 38, 57-106.
23. Brighty, K. E., Gootz, T. D., Girard, A., Sutcliffe, J. A., Castaldi, M. J., Girard, D. et al. (1993). 7-(3-azabicyclo[3.1.0]hexyl)quinolone antibacterial agents: synthesis and biological evaluation resulting in identification of CP-99,219. In Program and Abstracts of the Thirty-Third Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, Louisiana, 1993. Abstract 1509, p. 395. American Society for Microbiology, Washington, DC.
24. Soejima, R. & Shimada, K. (1989). Tosufloxacin tosylate. Drugs of the Future 14, 536-8.
25. 1substituents of quinolone antibacterials. Journal of Medicinal Chemistry 34, 131-9.
26. Ross, D. L. & Riley, C. M. (1990). Aqueous solubilities of some variously substituted quinolone antimicrobials. International Journal of Pharmaceutics 63, 237-50.
27. Brighty, K, E., Gootz, T. D., Girard, A., Shanker, R., Castaldi, M. J., Girard, D. et al. (1994). Prodrugs of CP-99,219 for intravenous administration; synthesis and evaluation resulting in identification of CP-116,517. In Program and Abstracts of the Thirty-Fourth Interscience Conference on Antimicrobial Agents and Chemotherapy, Orlando, FL, 1994. Abstract F28, p. 55. American Society for Microbiology, Washington, DC.
28. Sörgel, F. & Kinzig, M. (1993). Pharmacokinetics of gyrase inhibitors. Part 1 : basic chemistry and gastrointestinal disposition. American Journal of Medicine 94, Suppl. 3A, 44S-55S.
29. Teng, R., Tensfeldt, T. G., Liston, T. E. & Foulds, G. (1996). Determination of trovafloxacin, a new quinolone antibiotic, in biological samples by reversed-phase high-performance liquid chromatography. Journal of Chromatography B: Biomedical Applications 657, 53-9.
30. Gooding, B. B. & Jones, R. N. (1993). In vitro antimicrobial activity of CP-99,219, a novel azabicyclo-naphthyridone. Antimicrobial Agents and Chemotherapy 37, 349-53.
31. Eliopoulos, G. M., Klimm, K., Eliopoulos, C. T., Ferraro, M. J. & Moellering, R. C. (1993). In vitro activity of CP-99,219, a new fluoroquinolone, against clinical isolates of Gram-positive bacteria. Antimicrobial Agents and Chemotherapy 37, 366-70.
32. Gootz, T. D. & McGuirk, P. R. (1994). New quinolones in development. Expert Opinion on Investigational Drugs 3, 93-114.
33. Child, J., Andrews, J., Boswell, F., Brenwald, N. & Wise, R. (1995). The in-vitro activity of CP-99,219, a new naphthyridone antimicrobial agent: a comparison with fluoroquinolone agents. Journal of Antimicrobial Chemotherapy 35, 869-76.
34. Mulazimoglu, L., Drenning, S. D. & Yu, V. L. (1995). In vitro activity of two novel oxazolidinones (U-100592 and U-100766), a new fluoroquinolone (CP-99,219-27) and a streptogramin (Synercid) against S. aureus and S. epidermidis. In Program and Abstracts of the Thirty-Fifth Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, 1995. Abstract F210, p. 149. American Society for Microbiology, Washington, DC.
35. Cunha, B. A., Hussain Qadri, S. M., Ueno, Y., Walters, E. A. & Domenico, P. (1997). Antibacterial activity of trovafloxacin against Gram-positive and Gram-negative isolates. Journal of Antimicrobial Chemotherapy 39, Suppl. B, 29-34.
36. Felmingham, D., Robbins, M. J., Ingley, K., Mathias, L, Bhogal, H., Leakey, A. et al. (1997). In-vitro activity of trovafloxacin, a new fluoroquinolone, against recent clinical isolates. Journal of Antimicrobial Chemotherapy 39, Suppl. B, 43-50.
37. Fuchs, P. C., Barry, A. L., Brown, S. D. & Sewell, D. L. (1996). In vitro activity and selection of disk content for disk diffusion susceptibility tests with trovafloxacin. European Journal of Clinical Microbiology and Infectious Diseases 15 678-82.
38. Klugman, K. & Wasas, A. (1995). In-vitro activity of the fluoroquinolone trovafloxacin against penicillin-sensitive and penicillinresistant Streptococcus pneumoniae. Journal of Antimicrobial Chemotherapy 36, 873-4.
39. Sefton, A. M., Maskell, J. P., Minassian, M. & Williams, J. D. (1995). Comparative in vitro activity of CP-99,219, a new quinolone, against respiratory pathogens. In Abstracts of the Seventh European Congress of Clinical Microbiology and Infectious Diseases, Vienna, Austria, 1995. Abstract 738, p. 143. European Society of Clinical Microbiology and Infectious Diseases.
40. Coque, T. M., Singh, K. V. & Murray, B. E. (1996). Comparative in-vitro study of the new fluoroquinolone trovafloxacin (CP99,219) against Gram-positive cocci. Journal of Antimicrobial Chemotherapy 37, 1011-6.
41. Shonekan, D., Handwerger, S. & Mildvan, D. (1997). Comparative in vitro activities of RP59500 (quinupristin/dalfopristin), CL 329,998, CL 331,002, trovafloxacin, clinafloxacin, teicoplanin and vancomycin against Gram-positive bacteria. Journal of Antimicrobial Chemotherapy, 39, 405-9.
42. Kenny, G. E. & Cartwright, F. D. (1995). Susceptibilities of Mycoplasma pneumoniae, Mycoplasma hominis and Ureaplasma urealyticum to a new quinolone: CP-99,219. In Abstracts of the Thirty-Fifth Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, 1995. Abstract F236, p. 154. American Society for Microbiology, Washington, DC.
43. Neu, H. C. & Chin, N. X. (1994). In-vitro activity of the new fluoroquinolone CP-99,219. Antimicrobial Agents and Chemotherapy 38, 2615-22.
44. Verbist, L. & Verhaegen, J. (1995). In vitro activity of CP99,219, a new fluoroquinolone. In Abstracts of the Seventh European Congress of Clinical Microbiology and Infectious Diseases, Vienna, Austria, 1995. Abstract 731, p. 141. European Society of Clinical Microbiology and Infectious Diseases.
45. Rolston, K. V. I., Ho, D. H., LeBlanc, B., Streeter, H. & Dvorak, T. (1997). In-vitro activity of trovafloxacin against bacterial isolates from patients with cancer. Journal of Antimicrobial Chemotherapy 39, Suppl. B, 15-22.
46. Knapp, J. S., Neal, S. W., Parekh, M. C. & Rice, R. J. (1995). In vitro activity of a new fluoroquinolone, CP-99,219, against strains of Neisseria gonorrhoeae. Antimicrobial Agents and Chemotherapy 39, 987-9.
47. Spangler, S. K., Jacobs, M. R. & Appelbaum, P. C. (1994). Activity of CP-99,219 compared with those of ciprofloxacin, grepafloxacin, metronidazole, cefoxitin, piperacillin, and piperacillintazobactam against 489 anaerobes. Antimicrobial Agents and Chemotherapy 38, 2471-6.
48. Gootz, T. D., Brighty, K. E., Anderson, M. R., Schmieder, B. J., Haskell, S. L, Sutcliffe, J. A. et al. (1994). In vitro activity of CP99,219, a novel 7-(3-azabicyclo[3.1.0]hexyl)naphthyridone antimicrobial. Diagnostic Microbiology and Infectious Disease 19, 235-43.
49. Morrissey, I. (1996). Bactericidal activity of trovafloxacin (CP99,219). Journal of Antimicrobial Chemotherapy 38, 1061-6.
50. Gootz, T. D., Zaniewski, R., Tankovic, J., Courvalin, P., Haskell, S., Schmieder, B. et al. (1996). Activity of trovafloxacin (CP99,219) against ciprofloxacin-resistant mutants of Streptococcus pneumoniae. In Abstracts of the Ninety-Sixth General Meeting of the American Society for Microbiology, New Orleans, LA, 1996. Abstract A113. American Society for Microbiology, Washington, DC.
51. Girard, A. E., Girard, D., Gootz, T, D., Faiella, J. A. & Cimochowski, C. R. (1995). In vivo efficacy of trovafloxacin (CP-99,219), a new quinolone with extended activities against Grampositive pathogens, Streptococcus pneumoniae and Bacteroides fragilis. Antimicrobial Agents and Chemotherapy 39, 2210-6.
52. Nau, R., Schmidt, T., Kaye, K., Froula, J. L. & Täuber, M. G. (1995). Quinolone antibiotics in therapy of experimental pneumococcal meningitis in rabbits. Antimicrobial Agents and Chemotherapy 39, 593-7.
53. Paris, M. M., Hickey, S. M., Trujillo, M., Shelton, S. & McCracken, G. H. (1995). Evaluation of CP-99,219, a new fluoroquinolone, for treatment of experimental penicillin- and cephalosporin-resistant pneumococcal meningitis. Antimicrobial Agents and Chemotherapy 39,1243-6.
54. Edelstein, P. H., Edelstein, M. A. C., Ren, J., Polzer, R. & Gladue, R. P. (1996). Activity of trovafloxacin (CP-99,219) against Legionella isolates: in vitro activity, intracellular accumulation and killing in macrophages, and pharmacokinetics and treatment of guinea pigs with L. pneumophila pneumonia. Antimicrobial Agents and Chemotherapy 40, 314-9.
55. Dalvie, D., Khosla, N. & Vincent, J. (1995). Metabolism of a new quinolone antibiotic, CP-99,219, in humans. In Proceedings of the Fourth International Society of Study of Xenobiotics (ISSX) Meeting, Seattle, Washington, 1995. Abstract 126, p. 126. International Society of Study of Xenobiotics.
56. Teng, R., Liston, T. E. & Harris, S. C. (1996). Multiple-dose pharmacokinetics and safety of trovafloxacin in healthy volunteers. Journal of Antimicrobial Chemotherapy 39, 955-63.
57. Teng, R., Harris, S. C., Nix, D. E., Schentag, J. J., Foulds, G. & Liston, T. E. (1995). Pharmacokinetics and safety of trovafloxacin (CP-99,219), a new quinolone antibiotic, following administration of single oral doses to healthy male volunteers. Journal of Antimicrobial Chemotherapy 36, 385-94.
58. Teng, R., Dogolo, L. C., Willavize, S. A., Friedman, H. & Vincent, J. (1997). Oral bioavailability of trovafloxacin with and without food in healthy volunteers. Journal of Antimicrobial Chemotherapy 39, Suppl. B, 00-00.
59. Vincent, J., Venitz, R., Teng, R., Baris, B. A., Willavize, S. A., Polzer, R. J. et al. (1997). Pharmacokinetics and safety of trovafloxacin in healthy male volunteers following administration of single intravenous doses of the prodrug, alatrofloxacin. Journal of Antimicrobial Chemotherapy 39, Suppl. B, 75-80.
60. Mann, H. J., Bitterman, P. B., Anderson, A. C., Teng, R., Johnson, A., Avery, M. et al. (1995). CP-99,219 penetration into human bronchial tissues and fluids following the administration of a single dose. In Abstracts of the Thirty-Fifth Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, 1995. Abstract F241, p. 155. American Society for Microbiology, Washington, DC.
61. Teng, R., Dogolo, L. C., Willavize, S. A. & Vincent, J. (1995). Effect of age and gender on the pharmacokinetics of CP-99,219, a new quinolone antibiotic, in healthy volunteers. In Program and Abstracts of the Thirty-Fifth Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, California, 1995. Abstract F238, p. 154. American Society for Microbiology, Washington, DC.
62. Argeudas-Mohs, A., Loaiza, C., Riviera, R., Vargas, S. L., Goodall, E. M. S., Bradley, J. S. et al. (1995). CSF penetration of iv trovafloxacin in children. First International Pediatric Infectious Diseases Conference (ESPID and PIDS), Monterey, California, 1995.
63. Dalvie, D. K., Khosla, N. B., Navetta, K. A. & Brighty, K. E. (1996). Metabolism and excretion of trovafloxacin, a new quinolone antibiotic, in Sprague-Dawley rats and beagle dogs. Drug Metabolism and Disposition 24, 1231-40.
64. Teng, R., Girard, D., Gootz, T. D., Foulds, G. & Liston, T. E. (1996). Pharmacokinetics of trovafloxacin (CP-99,219), a new quinolone, in rats, dogs and monkeys. Antimicrobial Agents and Chemotherapy 40, 561-6.
65. Mayne, J. T., Johnson, N. J., Kluwe, W. M., Lencoski, D. L. & Polzer, R. J. (1997). A study of the phototoxic potential of trovafloxacin in BALB/c mice. Journal of Antimicrobial Chemotherapy 39, Suppl. B, 67-73.
66. Vincent, J., Teng, R., Dogolo, L. C. & Willavize, S. A. (1995). Effect of steady-state CP-99,219 on the pharmacokinetics of single and multiple doses of theophylline in healthy male volunteers. In Abstracts of the Thirty-Fifth Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, 1995. Abstract F239, p. 155. American Society for Microbiology, Washington, DC.
67. Takagi, K., Yamaki, K., Nadai, M., Kuzuya, T. & Hasegawa, T. (1991). Effect of a new quinolone, sparfloxacin, on the pharmacokinetics of theophylline in asthmatic patients. Antimicrobial Agents and Chemotherapy 35, 1137-41.